U.S. flag

An official website of the United States government, Department of Justice.

Prescription Drug Monitoring Program: Florida State Profile (2021)

NCJ Number
303644
Date Published
2021
Length
12 pages
Annotation

The Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) reports 2020 data and 2021 features of the Florida State Prescription Drug Monitoring Program.

Abstract

The name of Florida’s PDMP is E-FORCSE (Electronic-Florida Online Reporting of Controlled Substances Evaluation), which is managed by the Florida Department of Health. The email address is provided, along with the URLs for the PDMP website and websites for enrollment, query, data upload, and statistics. Contact information is provided for the Program Manager and the Program Operations Administrator. For 2020, the state population was 21,570,527. There were 100,171 DEA-registered drug prescribers and 5,083 DEA-registered drug dispensers. There are 18 types of reports available from the PDMP. Funding for 2021 is from the regulatory board fund and a CDC grant. The staff consists of four employees who are responsible for operations. Data on PDMP policies and procedures address key dates in the PDMP development, access information on relevant statutes and rules, and a listing of miscellaneous capabilities and policies. A data retention policy is indicated. Categories are listed for vocational personnel for whom PDMP training is available. Training is required before PDMP use by prescribers, dispensers, law enforcement, the Regulatory Board, and the Attorney General. Criteria for persons with PDMP accounts are reported. Law enforcement officials can access the PDMP only if there is an active investigation. Access is online through a web portal. Criteria for querying PDMP are listed. Prescribers and dispensers are required to use the PDMP but are not required to enroll. PDMP policies for veterinarians only require that a veterinary icon be on a PDMP report. Veterinarians are exempted from enrollment as data reporters, and their access is not authorized. Drug data monitored includes Schedules II-V. Data on pharmaceutical manufacturers/distributors sales can be monitored.

Date Published: January 1, 2021